HemOnc Today
@hemonctoday
The content you need, when you need it.
ID: 27645777
http://www.healio.com/HemOnc 30-03-2009 14:27:06
23,23K Tweet
12,12K Followers
1,1K Following
“It’s really exciting. It’s a new frontier for our patients.” Ravi Uppaluri, MDPhD of Dana-Farber discussed data from KEYNOTE-689 trial that showed KEYTRUDA (pembrolizumab) significantly extended EFS for patients with advanced HNSCC. AACR Brigham and Women's Hospital Harvard Medical School bit.ly/3YPEsdE